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Zoja C, Corna D, Gagliardini E, Conti S, Arnaboldi L, Benigni A,
Remuzzi G. Adding a statin to a combination of ACE inhibitor and ARB
normalizes proteinuria in experimental diabetes, which translates into full
renoprotection. Am J Physiol Renal Physiol 299: F1203–F1211, 2010. First
published August 18, 2010; doi:10.1152/ajprenal.00045.2010.—The capac-
ity of renin-angiotensin system (RAS) inhibitors to delay progression
of diabetic nephropathy depends on the time at which therapy is
started. A multimodal intervention is required to afford renoprotection
in overt diabetic nephropathy. Here we assessed the effects of maxi-
mal RAS inhibition by angiotensin-converting enzyme (ACE) inhib-
itor plus angiotensin II type 1 receptor blocker (ARB) in combination
with statin in rats with overt diabetic nephropathy. Uninephrecto-
mized rats made diabetic by streptozotocin were orally treated from 4
(when proteinuria and renal lesions had developed) to 8 mo with
vehicle, lisinopril plus candesartan, lisinopril plus candesartan plus
rosuvastatin, or rosuvastatin alone. Systolic blood pressure increased
in diabetic rats and was significantly lowered by combined therapies.
Dual RAS blockade significantly reduced proteinuria compared with
vehicle. Addition of statin further lowered proteinuria to control
levels. Glomerulosclerosis was ameliorated by RAS inhibitors or
statin, and regression was achieved by the addition of statin. Loss of
podocytes of diabetic rats was limited by ACE inhibitor plus ARB
while normalized by the three drugs. Defective nephrin expression of
diabetes was increased by dual RAS blockade or statin and restored by
the triple therapy. Tubular damage, interstitial inflammation, and
expression of the fibrotic markers transforming growth factor
(TGF)-1 and phosphorylated Smad 2/3 in tubuli were significantly
reduced by the triple regimen. These data suggest a strategy to target
proteinuria to try to achieve regression of renal disease in diabetic
patients who do not fully benefit from RAS inhibition alone.
dual renin-angiotensin system blockade; rosuvastatin; streptozotocin-
induced diabetes; glomerulosclerosis; tubular inflammation and fibro-
sis
DIABETES MELLITUS IS EMERGING as a global health care problem
with devastating human, social, and economic impact, such
that the total number of people with diabetes is projected to rise
from 171 million in 2000 to 366 million in 2030 (54). About
one-third of diabetic patients develop diabetic nephropathy,
which accounts for 40% of new cases of end-stage renal
disease (38). Diabetic nephropathy is associated with a dra-
matic excess of cardiovascular morbidity, and cardiovascular
mortality is the primary cause of early death in diabetic patients
(30). In proteinuric chronic nephropathies, inhibitors of the
renin-angiotensin system (RAS) are effective in reducing pro-
teinuria and slowing renal disease progression owing to their
actions on systemic and glomerular hypertension as well as to
their unique property of ameliorating size selectivity of the
glomerular barrier, thereby limiting excess protein ultrafiltra-
tion and its deleterious consequences (1, 37). The capacity of
RAS inhibitors to delay progression of diabetic nephropathy,
however, crucially depends on the time at which therapy is
started. Thus, in rats with streptozotocin-induced diabetes,
early administration of angiotensin-converting enzyme (ACE)
inhibitor significantly reduced systemic blood pressure and
normalized urinary protein excretion. By contrast, a late inter-
vention was unable to limit proteinuria despite an effective
control of blood pressure (31). Results of clinical trials have
shown that ACE inhibitors prevent the progression to overt
nephropathy in the early microalbuminuric phase of diabetes
(24, 33), whereas in a more advanced phase ACE inhibitors or
angiotensin II type 1 receptor blockers (ARB) provide imper-
fect protection (8, 20, 41). A more complex strategy than single
pharmacological intervention in the RAS may therefore be
required to afford renoprotection in diabetic patients with overt
nephropathy. The combination of an ACE inhibitor and an
ARB has been suggested as a way to maximize RAS blockade
by affecting both the bioavailability and the activity of angio-
tensin II (32, 56). Metanalysis of randomized trials in patients
with or without diabetes indicated that proteinuria reduction is
greater when ACE inhibitor and ARB are used together (18),
suggesting that a more efficient amelioration of the glomerular
barrier can be obtained by the combined therapy (32), which
might translate into increased renoprotection (42). Recently,
the Ongoing Telmisartan Alone and in Combination with
Ramipril Global Endpoint Trial (ONTARGET) (23) in patients
with atherosclerotic vascular disease or diabetes with end-
organ damage reported that although combination therapy
reduced albuminuria to a greater extent than monotherapy, it
worsened major renal outcomes. This study, however, had
several weak points—as recently highlighted (43)—and the
conclusions on dual RAS blockade are far from robust.
Statins or 3-hydroxy-3-methylglutaryl coenzyme A (HMG
CoA) reductase inhibitors have pleiotropic properties that com-
plement their cholesterol-lowering effects. In addition to inhibit-
ing the rate-limiting step in cholesterol biosynthesis, namely, the
conversion of HMG CoA into mevalonate, statins interfere with
prenylation of Ras and Rho family small GTP-binding proteins,
thereby blocking the activation of signaling pathways and tran-
scription factors, which regulate inflammatory and fibrogenic
genes critical to renal disease progression (25).
A multimodal intervention strategy using all available tools
to target urinary proteins has been envisioned as a rational
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approach to maximizing renoprotection in patients with
chronic renal disease (44). Experimental data support this
notion (57). Indeed, in rats with severe passive Heymann
nephritis that only partially responded to ACE inhibitor ther-
apy, the addition of statin to a chronic background of ACE
inhibition and ARB induced remission of proteinuria and
conferred complete protection of the kidney (57).
In the present study we wanted 1) to establish whether reno-
protection can be better achieved by a multidrug approach with
ACE inhibitor and ARB combined with statin than by dual RAS
blockade in a setting of severe diabetic nephropathy and 2) to
understand the mechanisms underlying the beneficial effects af-
forded by the triple therapy by looking at its impact in maintaining
glomerular and tubulointerstitial structure and function.
MATERIALS AND METHODS
Animals and Experimental Design
Male Sprague-Dawley rats (Charles River Italia, Calco, Italy) with
initial body weights of 270–330 g were used. Animal care and
treatment were conducted in accordance with institutional guidelines
that are in compliance with national (Decreto Legislativo n.116,
Gazzetta Ufficiale suppl 40, 18 febbraio 1992, Circolare n.8, Gazzetta
Ufficiale 14 luglio 1994) and international (EEC Council Directive
86/609, OJL358-1, December 1987; Guide for the Care and Use of
Laboratory Animals, U.S. National Research Council, 1996) laws and
policies. Animal protocols were submitted to and approved by the
Institutional Animal Care and Use Committee (IACUC) of “Mario
Negri” Institute, Milan, Italy. All animals were housed in a room in
which the temperature was kept constant on a 12:12-h dark-light cycle
and allowed free access to standard diet containing 20% protein by
weight and tap water. Animals were subjected to right nephrectomy
under anesthesia 7 days before the induction of diabetes in order to
hasten the development of the disease (3). Diabetes was induced by a
single intravenous injection of streptozotocin (60 mg/kg body wt;
Sigma, St. Louis, MO). The presence of diabetes was confirmed 2
days later by the measurement of the tail blood glucose level with a
reflectance meter (A. Menarini Diagnostics, Florence, Italy). Diabetic
rats received daily evening injections of insulin (Ultratard HM,
Nordisk Farmaceutici, Rome, Italy) in doses individually adjusted to
maintain a blood glucose level between 200 and 450 mg/dl. Blood
glucose levels were monitored at least twice a week in all diabetic rats
and occasionally in control animals for comparison. At month 4 after
diabetes induction (when proteinuria developed), rats were divided
into four groups and treated until month 8 as follows: group 1 (n 8),
vehicle (0.5% carboxymethylcellulose by gavage); group 2 (n  6),
lisinopril (12.5 mg/l in the drinking water) (3) plus candesartan (1
mg/kg in 0.5% carboxymethylcellulose by gavage) (4); group 3 (n 
8), lisinopril plus candesartan plus rosuvastatin (5 mg/kg by gavage);
group 4 (n  6), rosuvastatin. Six normal animals given carboxym-
ethylcellulose by gavage served as controls. An additional five dia-
betic rats together with four age-matched normal rats were killed at 4
mo after disease induction (before treatment) for renal histology
analysis.
Systolic blood pressure (SBP) was recorded by the tail cuff method
at baseline and at months 4 (before treatment) 6, and 8. Urinary
excretion of proteins was measured in 24-h urine samples collected in
metabolic cages at baseline and at different time intervals by the
modified Coomassie blue G dye-binding assay for proteins with
bovine serum albumin as standard. Urinary albumin excretion was
determined before treatment started and at the end of the study by
ELISA (Nephrat Exocell, Philadelphia, PA). Serum levels of creati-
nine, cholesterol, and triglycerides were measured by Reflotron test
(Roche Diagnostic, Indianapolis, IN). Urinary creatinine was mea-
sured by ELISA (Nephrat Exocell). Creatinine clearance rate was
calculated as urinary creatinine  urine volume/serum creatinine and
expressed as milliliters per minute per 100 g.
Renal Histology
The removed kidneys were fixed overnight in Duboscq-Brasil,
dehydrated in alcohol, and embedded in paraffin. Kidney samples
were sectioned at 3-m intervals (Ultrotome V, LKB, Bromma,
Sweden), and the sections were stained with Masson trichrome,
hematoxylin and eosin, and periodic acid Schiff reagent (PAS stain).
At least 100 glomeruli were examined for each animal, and the extent
of glomerular damage was expressed as the percentage of glomeruli
presenting sclerotic lesions. Tubular changes (atrophy, casts, and dilation)
were graded from 0 to 4 (0, no changes; 1, changes affecting25% of the
sample; 2, changes affecting 25–50% of the sample; 3, changes affecting
50–75% of the sample; 4, changes affecting 75–100% of the sample). All
renal biopsies were analyzed by the same pathologist, who was unaware
of the nature of the experimental groups.
Estimation of Glomerular Volume and Podocyte Count
Glomerular volume was calculated with the use of a computer-based
image analysis system (Image J 1.42q, http://rsb.info.nih.gov/ij) as
previously described (22). Podocytes were identified with an antibody
directed against Wilms tumor 1 (WT1), a podocyte-specific marker. The
estimation of the average number of podocytes per glomerulus was
determined in 30 glomeruli for each animal by morphometric analysis as
proposed by Weibel (51) on digital images acquired by fluorescence
microscopy (Olympus IX70) as previously reported (21).
Immunohistochemical Analysis
Indirect immunofluorescence was performed for the detection of
interstitial macrophage infiltration (14) and adipophilin staining. Al-
kaline phosphatase-fast red technique was used to evaluate transform-
ing growth factor (TGF)-1 expression (35). Immunoperoxidase
method (2) was employed for nephrin and phosphorylated (p)Smad
2/3 detection. The following primary antibodies were used: mouse anti-ED1
antigen present in rat monocytes/macrophages (1:100, Chemicon
International, Temecula, CA), rabbit anti-TGF-1 (1:100, Santa Cruz
Biotechnology, Santa Cruz, CA), goat anti-nephrin (1:100, Santa
Cruz), goat anti-pSmad 2/3 (1:50, Santa Cruz), and mouse anti-
adipophilin (1:50, Progen Biotech, Heidelberg, Germany). ED1-
positive cells were counted in 15 randomly selected high-power
microscopic fields (400) on average per animal. Adipophilin stain-
ing was evaluated in 13 randomly selected microscopic fields (200)
on average per animal, and the percentage of area occupied by
adipophilin-positive signal was quantified by setting a “threshold”
with Image J’s thresholding tool (1.42q, http://rsb.info.nih.gov/ij).
Intensity of tubular TGF-1 and pSmad 2/3 and glomerular nephrin
signals were graded on a scale of 0 to 3 (0, no staining; 1, weak
staining; 2, staining of moderate intensity; 3, strong staining) in 20
randomly selected tubulointerstitial microscopic fields (200) or 30
glomeruli on average per animal. Negative controls were obtained by
omitting the primary antibody on adjacent sections.
Lipid Extraction and Free Cholesterol and Cholesteryl
Ester Analysis
Kidneys were thawed and homogenized with chloroform-methanol
(2:1), BHT 0.01%, and KCl 0.05% plus a known amount of stigmas-
terol and cholesteryl heptadecanoate (synthesized by Prof. Ermanno
Valoti’s laboratory, Universita` degli Studi di Milano, Milan, Italy) as
internal standards. Two extractions were performed after 3-h shakings
at 4°C and the organic phase was dried under nitrogen and resus-
pended in chloroform-methanol (2:1) plus BHT. The aqueous phase
was dried, and the resulting pellet was dissolved in 0.1 N NaOH. Total
protein amount was measured and results are expressed as micro-
grams of lipid per milligram of protein (40).
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An aliquot of the lipid extract was loaded onto prerun and activated
channeled Silica TLC plates (BioMap) in hexane-diethyl ether-acetic
acid (80:20:1 vol/vol/vol). After the run, the plates were sprayed with
dichlorofluorescein (0.15% in ethanol) and the spots corresponding to
those of known standards of free and esterified cholesterol were
scraped off. Free cholesterol was extracted from silica with hexane-
isopropanol and detected without derivatization. Cholesteryl esters
were derivatized with methanol-HCl 3 N-toluene for 2 h at 75°C. The
analysis was performed on a DANI 1000 gas liquid chromatographer
(GLC) (DANI Instruments, Milan, Italy) equipped with a flame
ionization detector and a 30-m, 0.32-mm, 0.25-m MEGA-1 (Mega
Columns, Legnano, Italy) fused silica column. The flow of hydrogen
was at a constant pressure of 1 bar, and the detector temperature was
300°C. Oven temperature ranged for free cholesterol from 185 to 300°C
(total run 15 min) and for cholesteryl esters from 160 to 300°C (total run
28 min). Chromatograms were recorded and the area of each peak
quantified by Clarity Software (Clarity, Prague, Czech Republic). The
mass of free cholesterol was calculated by comparing its area with that of
the internal standard (stigmasterol), while the mass of cholesteryl esters
was evaluated after integrating and summing the areas of each fatty acid
composing the ester and comparing the total area with that of the internal
standard (cholesteryl heptadecanoate) (49).
Statistical Analysis
Results are expressed as means  SE. Data were analyzed by
ANOVA with the Bonferroni post hoc analysis for multiple compar-
ison or nonparametric Kruskal-Wallis test. The statistical significance
level was defined as P  0.05.
RESULTS
Systemic Parameter
By the end of the study one rat died in each group of diabetic
rats. All control rats were alive. Diabetic rats gained weight
with time, although to a lesser extent than control rats (Table 1).
At the end of the study, mean body weights of rats given a
combination of lisinopril and candesartan or lisinopril plus
candesartan plus rosuvastatin were significantly lower (P 
0.05) than those of diabetic rats treated with vehicle or statin
alone. Food intake was comparable among diabetic rats and
significantly higher than that of control rats (Table 1).
As shown in Table 1, serum cholesterol levels were compa-
rable among the groups of diabetic and control rats. Serum
triglyceride levels were significantly increased in diabetic rats
given vehicle compared with control rats. Hypertriglyceride-
mia was reduced in all diabetic treated rats, as a likely conse-
quence of the antiproteinuric effect of the therapy, although
statistical significance was not achieved.
Rats with diabetes showed over time a significant increase in
SBP compared with control rats (Fig. 1). Treatment with ACE
inhibitor plus ARB, or with the addition of rosuvastatin,
maintained SBP at values significantly lower than those of the
vehicle group and even of age-matched control rats. In rats
given rosuvastatin alone, SBP values were numerically lower
than those measured in vehicle-treated rats, which is in line
with the antihypertensive effects reported for statins (13, 27)
and attributed to drug interaction with endothelial function or
angiotensin II receptors (7).
Renal Parameters
The time course of urinary protein excretion is shown in Fig. 2A.
At 4 mo, rats with diabetes exhibited significantly higher
values of urinary protein excretion than control rats and were
randomized to receive treatments. Proteinuria progressively
increased in rats given vehicle, averaging 94  24 mg/day at 8
mo. Combined administration of lisinopril and candesartan
reduced proteinuria compared with pretreatment, and levels
were significantly (P  0.05) lower than those measured in
vehicle-treated rats (month 8, 38  12 mg/day). Remarkably,
when rosuvastatin was added on top of dual RAS blockade,
proteinuria was further lowered and normalized (month 8,
24  2 mg/day; P  0.01 vs. vehicle) to the levels of control
rats (month 8, 25  3 mg/day). In diabetic rats treated with
rosuvastatin the mean proteinuria levels were numerically
lower than those measured in rats receiving vehicle (month 8,
78  20 mg/day). A similar trend was observed for urinary
albumin excretion (Fig. 2B).
Table 1. Systemic parameters measured in diabetic rats at 8 mo after disease induction
Groups Body Wt, g
Food Intake,
g/24 h
Serum Cholesterol,
mg/dl
Serum Triglycerides,
mg/dl
Creatinine Clearance,
ml · min1 · 100 g1
Diabetes
Vehicle 472 15† 41  2† 110  9 195 30* 0.26 0.03
Lisinopril 	 candesartan 422 6†‡§ 43  3* 102  2 126 18 0.30 0.02
Lisinopril 	 candesartan 	 rosuvastatin 417 14†‡ 40  4* 106  3 124 15 0.27 0.02
Rosuvastatin 483 32* 39  3* 102  2 147 15 0.25 0.01
Control 607 21 24  2 100  0 112 8 0.29 0.01
Values are expressed as means  SE. *P  0.05, †P  0.01 vs. control rats; ‡P  0.05 vs. vehicle; §P  0.05 vs. rosuvastatin.
Fig. 1. Time course of systolic blood pressure in control and diabetic rats
treated with vehicle, lisinopril 	 candesartan, lisinopril 	 candesartan 	
rosuvastatin ,or rosuvastatin, from 4 to 8 mo. Data are means SE. *P 0.05,
**P  0.01 vs. control; °°P  0.01 vs. vehicle; #P  0.05, ##P  0.01 vs.
rosuvastatin at corresponding time.
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Renal function, as evaluated by creatinine clearance at
month 8, was mildly impaired in diabetic rats given vehicle
compared with control rats (Table 1). Treatments did not
significantly affect renal function.
Glomerular Pathology
Histology. Morphological evaluation of the kidney in dia-
betic rats at 4 mo revealed the presence of 2  0.01% sclerotic
glomeruli on average (P  0.05 vs. age-matched control rats:
0.08  0.002%) (Fig. 3). At 8 mo diabetic rats given vehicle
showed variable degrees of glomerulosclerosis and hyalinosis
with segmental collapse of the glomerular tuft affecting 10.6
1.8% of glomeruli on average (P  0.01 vs. diabetes at 4 mo;
P  0.01 vs. age-matched control rats: 2.2  0.4%). Admin-
istration of lisinopril plus candesartan decreased the incidence
of glomerulosclerosis (4.9  1.6%), but not to a significant
extent. A complete protection was instead conferred by the
addition of rosuvastatin to the RAS inhibitors, so that the
percentage of glomeruli with sclerotic changes (1.2  0.3%)
was lower than that observed in diabetic animals at 4 mo,
thereby suggesting regression of glomerular lesions. Rosuvas-
tatin treatment limited the degree of glomerulosclerosis (5.7 
1.6%), but without reaching a statistical significance compared
with vehicle.
Morphometric analysis: glomerular volume, podocyte num-
ber, and nephrin expression. Glomerular hypertrophy was
observed in diabetic rats receiving vehicle (Fig. 4A). Treat-
ments with lisinopril plus candesartan or rosuvastatin alone
numerically reduced the glomerular volume. A significant
reduction (P  0.05) of glomerular hypertrophy was achieved
after the triple therapy. The number of podocytes per glomer-
ulus was significantly decreased in diabetic rats given vehicle
compared with control rats (P  0.05). Loss of podocytes per
glomerulus was limited by dual RAS blockade. Treatment with
the triple therapy restored the number of podocytes to control
values (Fig. 4A). Only a partial effect on podocyte number was
observed after treatment with rosuvastatin alone. An intense
expression of nephrin protein with the typical epithelial-like
staining pattern was detected in glomeruli of control rats
(score: 2.70  0.08, Fig. 4Be). Diabetic rats given vehicle
showed a significant (P  0.01) reduction in nephrin expres-
sion (score: 1.49 0.19, Fig. 4Ba) compared with control rats.
Nephrin staining was markedly increased after the administra-
tion of either lisinopril plus candesartan (score: 2.23  0.13,
P  0.05 vs. vehicle; Fig. 4Bc) or rosuvastatin alone (score:
2.22  0.22, P  0.05 vs. vehicle; Fig. 4Bb). Notably, in
diabetic animals receiving the triple therapy nephrin expression
was restored, so that levels were similar to those of control
animals (score: 2.68  0.06, P  0.01 vs. vehicle; Fig. 4Bd).
Tubulointerstitial Pathology
Histology. In diabetic rats glomerular injury was associated
with mild tubular damage (Fig. 5A), which increased with time
from 4 mo (score: 0.60  0.24) to 8 mo (score: 1.01  0.03,
P  0.01 vs. controls: 0.16  0.12). Tubular lesions were
significantly reduced by combined treatment of lisinopril and
candesartan (score: 0.25  0.25, P  0.05 vs. vehicle) and
normalized by the triple therapy (score: 0.13  0.13, P  0.01
Fig. 3. Incidence of glomerulosclerosis in diabetic animals at 4 mo (before
treatment) and 8 mo after administration of vehicle, rosuvastatin, lisinopril 	
candesartan, or lisinopril 	 candesartan 	 rosuvastatin and in control rats.
Values are expressed as means  SE. *P  0.05, **P  0.01 vs. control at
corresponding time; $P  0.05, $$P  0.01 vs. vehicle at 4 mo; °°P  0.01
vs. vehicle at 8 mo; #P  0.01 vs. rosuvastatin.
Fig. 2. A: time course of urinary protein excretion in control and diabetic rats
treated with vehicle, lisinopril 	 candesartan, lisinopril 	 candesartan 	
rosuvastatin, or rosuvastatin from 4 to 8 mo. B: urinary albumin levels at 4 mo
(before treatment) and 8 mo. Data are means  SE. *P  0.05, **P  0.01
vs. control; °P  0.05, °°P  0.01 vs. vehicle; #P  0.05, ##P  0.01 vs.
rosuvastatin at corresponding time.
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vs. vehicle). In diabetic rats given rosuvastatin the score of
tubular damage averaged 0.60  0.24.
Interstitial inflammation and fibrosis. Accumulation of ED1-
positive monocytes/macrophages was found in peritubular cor-
tical interstitium of diabetic rats given vehicle (Fig. 5B).
Treatment with lisinopril plus candesartan numerically reduced
the interstitial accumulation of inflammatory cells compared
with vehicle. A further significant reduction was observed after
the triple therapy. Rosuvastatin alone limited inflammatory cell
infiltrates to an extent similar to the combined treatment of
ACE inhibitor and ARB. Tubular lesions and interstitial in-
flammation observed in diabetic animals given vehicle were
accompanied by increased tubular expression of the profibrotic
marker TGF-1 (Fig. 6). TGF-1 staining was decreased after
ACE inhibitor plus ARB treatment (Fig. 6C) compared with
vehicle-treated rats (Fig. 6A). A further reduction was observed
after the triple regimen (Fig. 6D), to the extent that TGF-1
expression was fairly comparable to that found in control rats
(Fig. 6E). A 24% reduction in tubular TGF-1 expression
compared with vehicle was observed after treatment with
rosuvastatin alone (Fig. 6B). Upregulation of tubular TGF-1
in diabetic rats given vehicle was associated with activation of
the intracellular cascade of Smad proteins, particularly pSmad
2/3 (6), which are specifically involved in the regulation of
Fig. 4. A: morphometric estimation of mean glomerular
volume and average number of podocytes per glomerulus
in diabetic rats (D) receiving vehicle, rosuvastatin, lisino-
pril 	 candesartan, or lisinopril 	 candesartan 	 rosuvas-
tatin and in control rats. Values are expressed as means 
SE. *P  0.05, **P  0.01 vs. control; °P  0.05 vs.
vehicle. B: representative photomicrographs of nephrin
expression by immunoperoxidase in diabetic animals re-
ceiving vehicle (a), rosuvastatin (b), lisinopril 	 candesar-
tan (c), or lisinopril 	 candesartan 	 rosuvastatin (d) and
in control rats (e). Staining was completely abrogated by
omitting the primary antibody on the adjacent section on
each slide, indicating staining specificity (f). Original mag-
nification 600.
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TGF--dependent fibrogenic responses (Fig. 7). The increased
pSmad 2/3 staining in tubuli of diabetic rats on vehicle (Fig.
7A) was partially, but not significantly, reduced by lisinopril
plus candesartan (Fig. 7C). A statistically significant difference
was achieved after the addition of rosuvastatin to the dual
therapy (Fig. 7D). Rosuvastatin alone (Fig. 7B) limited tubular
pSmad 2/3 expression to an extent similar to that of the dual
therapy.
Renal Lipid Accumulation
Lipid analysis revealed a numerically increased free and
esterified cholesterol content in the kidneys of diabetic rats
receiving vehicle (Table 2). A trend toward a decrease in
cholesterol was observed in the kidneys of rats treated with
rosuvastatin, alone or in association with the other regimens,
although statistical significance was not reached. Treatment
with lisinopril plus candesartan showed only a modest effect in
reducing lipid accumulation, confined to the esterified form of
cholesterol (Table 2).
The immunolocalization of adipocyte differentiation-related
protein adipophilin, a marker of cytoplasmic lipid droplets
(16), revealed almost no lipid droplets in control rats and a
significant increase of the typical lipid droplets as ring-shaped
red dots in the tubules of diabetic rats on vehicle (Table 2). The
accumulation of lipid droplets was significantly reduced by
combined treatment with lisinopril and candesartan and by the
triple therapy. Rosuvastatin alone also reduced tubular adi-
pophilin expression to a significant extent (Table 2).
DISCUSSION
Results from the present study demonstrate that in rats with
overt diabetic nephropathy that benefited only partially from
ACE inhibitor treatment (3, 14), the addition of candesartan to
#
Fig. 6. Scores (top) and representative photomicrographs (bottom) of tubular
transforming growth factor (TGF)-1 expression in diabetic rats receiving
vehicle (A), rosuvastatin (B), lisinopril 	 candesartan (C), or lisinopril 	
candesartan 	 rosuvastatin (D) and in control rats (E). Staining was com-
pletely abrogated by omitting the primary antibody on the adjacent section on
each slide, indicating staining specificity (F). Original magnification  200.
Score values are expressed as means SE. **P 0.01 vs. control; °P 0.05,
°°P  0.01 vs. vehicle; #P  0.05 vs. rosuvastatin.
Fig. 5. Tubular damage (A) and interstitial accumulation of ED1-positive
monocytes/macrophages (B) in diabetic rats after administration of vehicle,
rosuvastatin, lisinopril 	 candesartan, or lisinopril 	 candesartan 	 rosuvas-
tatin and in control rats. Values are expressed as means  SE. *P  0.05,
**P  0.01 vs. control; °P  0.05, °°P  0.01 vs. vehicle. HPF, high-power
field.
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lisinopril reduced proteinuria to a significant extent compared
with diabetic rats receiving vehicle and markedly, albeit not
significantly, ameliorated the degree of glomerulosclerosis.
When rosuvastatin was added on top of ACE inhibition and
angiotensin II type 1 receptor blockade, proteinuria was low-
ered to levels of control rats, indicating restoration of the
glomerular barrier function, and full protection of the kidney
was obtained. The mechanism(s) underlying the strong anti-
proteinuric effect afforded by the triple therapy in diabetic rats
could be related to the combined drugs’ action on glomerular
filtration barrier function. Abnormalities in size-selective func-
tion of the glomerular capillary wall have been consistently
shown by dextran or Ficoll fractional clearance studies in
experimental and human diabetes, with increase in the number
of large nonselective pores responsible for the passage of
circulating macromolecules in the urinary space (14, 29, 36,
39, 41). Both ACE inhibitors and ARB reduced pore dimen-
sions and improved size selectivity of the glomerular mem-
brane in rats with streptozotocin-induced diabetes (14, 36) and
in patients with type 1 diabetes (29) which translated into a
reduction of proteinuria. That statins may ameliorate diabetes-
induced changes in glomerular permeability has been sug-
gested by recent data showing that treatment with rosuvastatin
resulted in near-normalization of the abnormal glomerular
filtration of 70- and 40-kDa dextrans in streptozotocin-diabetic
rats (28). The favorable effects of rosuvastatin on glomerular
permeability were possibly related to statin’s ability to inhibit
the activation of Rho signaling pathways shown to decrease
endothelial barrier function (10).
Podocytes span the glomerular capillaries and function via
the slit diaphragm as a critical barrier to macromolecule filtra-
tion (46). Studies have highlighted that reduction in podocyte
number is an early feature of diabetic nephropathy that predicts
long-term urinary albumin excretion and progressive course of
the disease (12, 26, 53). Reduced podocyte number can reflect
increased podocyte detachment and/or apoptosis (48, 55). As a
consequence of podocyte depletion, the remaining podocytes
are induced to cover the denuded basement membrane,
whereas the mesangial compartment expands to further com-
pensate for the ongoing cell loss (46), which would favor
glomerular hypertrophy in diabetes. In the present study we
confirmed a reduced podocyte number per glomerulus in dia-
betic rats given vehicle, which was associated with increased
glomerular volume and the development of glomerulosclerosis.
The dual blockade of RAS with lisinopril and candesartan
markedly limited podocyte loss, but only triple therapy resulted
in a complete preservation of podocyte number and a reduction
of glomerular volume. That RAS inhibitors can influence
podocyte loss has been previously documented in diabetic rats
(14, 15). An interesting finding here is that the administration
of rosuvastatin alone partially limited podocyte loss of diabetic
rats. Among possible mechanisms, recent in vitro data have
shown that rosuvastatin protected injured podocytes from un-
dergoing apoptosis through upregulation of the cell cycle
Table 2. Free and esterified cholesterol levels and
adipophilin expression in kidney tissue of diabetic rats at 8
mo after disease induction
Groups
Free
Cholesterol,
g/mg protein
Esterified
Cholesterol,
g/mg protein
Adipophilin
Expression, %
Diabetes
Vehicle 65.04 2.42 4.20  0.53 1.80  0.1*
Lisinopril 	 candesartan 66.20 3.53 3.36  0.23 0.50  0.3†
Lisinopril 	 candesartan 	
rosuvastatin
54.46  4.23 3.21  0.40 0.51  0.5†
Rosuvastatin 58.18 2.39 3.24  0.12 0.72  0.3†
Control 62.31 4.90 3.40  0.82 0.27  0.5
Values are expressed as means  SE. *P  0.01 vs. control rats; †P  0.01
vs. vehicle.
Fig. 7. Scores (top) and representative photomicrographs (bottom) of tubular
phosphorylated (p)Smad 2/3 expression in diabetic rats given vehicle (A),
rosuvastatin (B), lisinopril 	 candesartan (C), or lisinopril 	 candesartan 	
rosuvastatin (D) and in control rats (E). Staining was completely abrogated by
omitting the primary antibody on the adjacent section on each slide, indicating
staining specificity (F). Original magnification 200. Score values are ex-
pressed as means  SE. *P  0.05 vs. control; °°P  0.01 vs. vehicle.
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regulator p21, a prosurvival player in podocyte apoptosis (11).
There is also evidence showing that statins may directly stim-
ulate Akt-dependent survival pathway in podocytes. Thus
treatment with statins reduced oxidized LDL-induced apopto-
sis in cultured human podocytes by activating Akt/phosphati-
dylinositol 3-kinase signaling pathway (9). In the same study,
it was shown that the statin-induced Akt activation also pro-
tected podocytes from the loss of nephrin, the slit diaphragm
protein that acts to maintain slit pore integrity and renal
filtration capacity (50), which would provide a mechanism for
the antiproteinuric effect of statins. In the present study, the
defective nephrin protein levels found in the glomeruli of
diabetic rats receiving vehicle were improved by rosuvastatin
to an extent similar to that of dual RAS blockade. While
improvement in nephrin expression after ACE inhibitor treat-
ment has been previously documented in both experimental (5,
14, 17) and human (19) diabetic nephropathy, few reports are
available showing the ability of statins to ameliorate decreased
expression of nephrin, and they refer to models of proteinuric
renal disease other than diabetic nephropathy (47, 52). Re-
markably, when rosuvastatin was added to lisinopril and can-
desartan, we obtained restoration of nephrin expression, which
paralleled the regression of proteinuria to normal values.
In the present study, we unequivocally showed that normal-
ization of proteinuria by the triple therapy translated into
preservation of the tubular structure, reduction of interstitial
inflammation, and almost complete abrogation of the abnormal
tubular expression of TGF-1, a central player in the fibro-
genic process of diabetic nephropathy (34, 45). Moreover, the
finding of reduced staining for pSmad 2/3 in the tubuli of rats
treated with ACE inhibitor plus ARB plus statin further indi-
cated the antifibrotic effects of the triple regimen. It has been
reported that in the profibrotic process TGF- signaling in-
volves TGF- receptor-activated Smad 2 and 3, which, once
phosphorylated, bind to Smad 4. The resulting Smad complex
translocates into the nucleus, where it cooperates with numer-
ous transcription factors to regulate the transcription of profi-
brogenic genes (6).
In conclusion, these data indicate that adding a statin to a
background of ACE inhibition and angiotensin II receptor
blockade therapy normalizes proteinuria and affords better
renoprotection than a dual RAS blockade in rats with overt
diabetic nephropathy. These results reinforce the concept that
targeting proteinuria is the best way to induce regression of
renal disease, and suggest this multidrug approach as a strategy
for both proteinuric diabetic and nondiabetic patients who do
not fully benefit from ACE inhibitor and ARB treatment.
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